Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Adenosine, an immunosuppressive molecule, promotes tumor growth and metastasis in various cancers.
• The CD73-adenosinergic pathway is implicated in cancer progression and can affect therapeutic efficacy.
• BRAF^V600E mutations are common in melanoma, and targeted therapies like dabrafenib and trametinib are clinically approved.

Purpose of the Study:

• To investigate the activity of the CD73-adenosinergic pathway in melanoma patients.
• To determine if adenosine restricts the efficacy of targeted therapies in BRAF^V600E melanoma.
• To evaluate the therapeutic potential of targeting this pathway in melanoma.

Main Methods:

• Assessed CD73 expression in AJCC stage III melanoma patients.
• Treated CD73⁺ BRAF^V600E-mutant melanoma cells with dabrafenib and trametinib.
• Utilized a mouse model to assess tumor initiation and metastasis with combined BRAF/MEK and A2A receptor inhibition.

Main Results:

• CD73 expression correlated with nodal metastasis in stage III melanoma patients.
• Targeted therapy (dabrafenib and trametinib) downregulated CD73 expression in tumor cells.
• Combined inhibition of BRAF/MEK and the A2A adenosine receptor significantly reduced tumor initiation and metastasis in mice.

Conclusions:

• The CD73-adenosinergic pathway is active in melanoma and associated with advanced disease.
• Targeting adenosine, in combination with BRAF/MEK inhibitors, shows promise for enhancing melanoma treatment.
• This strategy may improve responses to targeted and immune-based therapies in melanoma patients.